TSI - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Real-Time Viable Particle Counters, like TSI’s BioTrak™ Products, are a new Rapid Microbial Methods (RMM) technique, which has recently been released to the market. These new products are based on the measurement technique of Laser-Induced Fluorescence (LIF). With LIF, essentially, when biological particles are excited by a specific wavelength of light, the emit light at a different, known wavelength. While most LIF based products use similar measurements, there are some considerable differences in products offered on the market.

The BioTrak Real-Time Viable Particle Counter is the only product that measures non-viable particles, just like Portable Particle Counters, and is capable of classifying a cleanroom. This establishes that room meets the specified airborne particulate cleanliness standard, matching previous measurements. The BioTrak Particle Counter also comes with excellent discrimination performance. Some of the early products on the market have had issues with determining viable from non-viable particles. This produces too many “false positives”, and provides uncertainty with customers that the measurement works. To address this issue, TSI has conducted extensive testing and developed algorithms that are proven to provide a much better level of discrimination.

Further, through an evaluation program, you should be able to test the BioTrak against typical sample plates and use that information to properly assess future measurements. Finally, the BioTrak Real-Time Viable Particle Counter comes with a unique built-in sample collection filter that can collect the same particles that were measured. Those samples can then be sent to a lab for more detailed evaluation.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here